A food-derived powder with one well-demonstrated action: taken with a starchy meal, it slows starch breakdown, so blood sugar arrives more gradually and the insulin response is smaller. Longer-term blood sugar, cholesterol and inflammation effects stay unsettled. Higher doses bring gas and loose stools. Nearly all of the glucose testing came from one company developing the ingredient. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Post-meal glucose peak (continuous glucose monitoring) | Peak below 120 mg/dL; return to baseline within 2–3 hours | The direct target of the mechanism |
| Fasting glucose | 70–85 mg/dL | Context for overall glycemic status |
| Glycated hemoglobin (HbA1c) | 4.8–5.3% | Whether the post-meal effect accumulates over months |
| Fasting insulin | 2–5 µIU/mL | Whether pancreatic demand falls as glucose spikes flatten |
| HOMA-IR | Below 1.0 | Composite read on insulin sensitivity |
| Triglycerides | Below 80 mg/dL | One of the lipid measures with a pooled positive signal |
| Low-density lipoprotein cholesterol (LDL-C) | Below 100 mg/dL | The lipid measure most tied to arterial risk |
| hs-CRP | Below 0.5 mg/L | Tracks the inflammation signal seen in pooled trials |
| Alanine aminotransferase (ALT) | 10–26 U/L (men), 7–22 U/L (women) | Liver context, given the split enzyme signal in pooled data |
| Ferritin | 50–150 ng/mL | Detects slow iron decline from polyphenol binding |
Cadence: Gut tolerance and the continuous glucose monitoring peak at 4 weeks; glycated hemoglobin, lipid panel, and high-sensitivity C-reactive protein at 12 weeks; then every 6–12 months once the dose is stable. Ferritin annually where mineral separation is not observed.